Mr. Ravenscroft has nearly 30 years of experience in the health care industry spanning senior product development and commercial management roles in North America, Europe and Asia.

Most recently, he served as President of Bristol-Myers Squibb's Medical Imaging Business. He was also Vice President of Bristol-Myers Squibb's Global Virology Franchise. Mr. Ravenscroft has held executive and senior positions with DuPont Pharmaceutical's Global HIV Business and GlaxoWellcome.

Mr. Ravenscroft holds a master's degree in Information Science from City University in the United Kingdom and a bachelor's degree in Applied Biology from North East London University.

Dr. Dropulic is one of the leading experts in Lentiviral Vector technology. He is a member of the Infectious Diseases and Industrial Liaisons Committees for the American Society of Gene Therapy and a member of the Editorial Board of the journal Human Gene Therapy.

Prior to founding Lentigen, he was Founder and Chief Scientific Officer of VIRxSYS where he successfully led a multidisciplinary team to initiate and complete the first ever Lentiviral Vector clinical trial in humans. Prior to founding VIRxSYS, Dr Dropulic was an Instructor and then Adjunct Assistant Professor at Johns Hopkins University School of Medicine in Baltimore, Maryland, where he was the first to develop a HIV-based vector targeted to inhibit the replication of the HIV/AIDS virus.

Dr. Dropulic was a Fogarty Fellow at the National Institutes of Health where he worked on developing transgenic animals using embryonic stem cell technology, understanding molecular aspects of HIV replication and gene therapy for HIV/AIDS. He obtained his Ph.D. from the University of Western Australia focusing upon how viruses cause disease in the body. Dr Dropulic received his B.Sc. (Hons.) from the University of Western Australia and a MBA from The Johns Hopkins University.